GlassScriptPhysician profile
Patrick J Klemawesch
NPI 1043293335
$1,484.54
in general payments reported to CMS, 2019-2025
21 companies · $175 in 2025
The $175 reported for 2025 was less than what a typical Allergy & Immunology (Internal Medicine) provider received nationally (typical 2025 total: $681).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47.72 · 2020: $95.87 · 2021: $186 · 2022: $227 · 2023: $406 · 2024: $347 · 2025: $175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $536 · Education: $392.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $536.27 |
| Education | $391.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $345.65 | 2020-2024 | Dupixent |
| Genzyme Corporation | $215.45 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $213.44 | 2023 | |
| Glaxosmithkline, LLC. | $102.86 | 2020-2024 | Nucala |
| Pharming Healthcare, INC. | $92.82 | 2021-2025 | Ruconest |
| Takeda Pharmaceuticals U.S.A., INC. | $73.60 | 2021-2025 | Cuvitru |
| Novartis Pharmaceuticals Corporation | $62.87 | 2025 | |
| Amgen INC. | $60.00 | 2022-2024 | Tezspire |
| Genentech USA, INC. | $55.80 | 2021-2024 | Xolair |
| Csl Behring | $49.52 | 2019-2023 | Haegarda |
| Pfizer INC. | $29.49 | 2020-2024 | |
| Aimmune Therapeutics, INC. | $27.24 | 2020 | |
| Leo Pharma INC. | $21.73 | 2022 | |
| Abbvie INC. | $21.43 | 2024 | |
| Uswm, LLC | $21.10 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $16.73 | 2025 | Nemluvio |
| Phadia US INC. | $16.50 | 2025 | Immunocap |
| Covis Pharma Gmbh | $15.64 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $15.55 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $14.03 | 2022 | |
| Optinose US, INC. | $13.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Klemawesch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.